HeartFlow has 6 close competitors: Abridge, Alloy Therapeutics, Commure.
Sector, valuation and status for each competitor.
company profile›
competitor›
competitor›
competitor›
competitor›A private valuation and a public market cap share one column; each row names its basis and date.
HeartFlowAbridgeCommureInnovaccerNeuralinkMedical technology company providing AI-powered non-invasive analysis of coronary artery disease (Heartflow One platform, including FFR-CT and Plaque Analysis).
HeartFlow competes with 6 companies here: Abridge, Alloy Therapeutics, Commure, HistoSonics, Innovaccer, Neuralink.
HeartFlow was last valued at $1.6B (Aug 2025). That price was agreed in one transaction and holds until the next round. A listed competitor is repriced every trading session.
Lead investors for each round are in the funding timeline.
The closest medical ai / cardiac diagnostics peers are on the competitors page.
The routes section explains what is realistically available for a company at this stage.
Yes. HeartFlow is listed on NASDAQ as HFLO.
The last valuation is $1.6B.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
